Malignant Rhabdoid Tumor
📧 Sign up to get email alerts when something new happens for Malignant Rhabdoid Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors [Phase 1, Phase 2]
A clinical trial update on a Phase 1/2 study of combining tazemetostat with nivolumab and ipilimumab in INI1/SMARCB1-deficient and SMARCA4-d…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]
Phase 1 trial evaluating an IL-15/IL-21 armored GPC3-targeted CAR-T cell therapy for pediatric solid tumors is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells [Phase 1]
Phase 1 pediatric trial of interleukin-15 and interleukin-21 armored glypican-3–specific CAR T cells for solid tumors, including liver-origi…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers [Phase 2]
This update describes a Phase 2 study of the combination of nivolumab and ipilimumab in children and young adults with INI1-negative cancers…
-
CLINICAL_TRIALS research · 2025-11-03Clinical Trial Update: Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells [Phase 1]
Phase 1 clinical trial evaluating GPC3-targeted CAR T cells armored with IL-15 and IL-21 for GPC3-positive solid tumors; currently recruitin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.